Published in Gastroenterology on July 01, 2002
The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology (2001) 3.60
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50
Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med (2010) 12.35
Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology (2011) 5.38
A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet (2006) 5.10
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology (2009) 3.73
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis (2012) 3.69
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis (2009) 3.66
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology (2011) 2.96
Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol (2012) 2.93
Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol (2013) 2.85
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol (2010) 2.74
The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology (2002) 2.58
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis (2012) 2.55
Antiendomysial and antihuman recombinant tissue transglutaminase antibodies in the diagnosis of coeliac disease: a biopsy-proven European multicentre study. Eur J Gastroenterol Hepatol (2005) 2.49
Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis (2010) 2.20
Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut (2013) 2.03
Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology (2012) 2.03
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut (2011) 1.80
Groups IV, V, and X phospholipases A2s in human neutrophils: role in eicosanoid production and gram-negative bacterial phospholipid hydrolysis. J Biol Chem (2001) 1.67
Anti-Saccharomyces cerevisiae antibodies: a stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatment. Am J Gastroenterol (2003) 1.54
Clinical presentation of venous thromboembolism in inflammatory bowel disease. J Crohns Colitis (2012) 1.49
Heterogeneous expression and regulation of CD40 in human hepatocellular carcinoma. Eur J Gastroenterol Hepatol (2003) 1.40
The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol (2007) 1.39
Aortic mural thrombi in patients with inflammatory bowel disease: report of two cases and review of the literature. Inflamm Bowel Dis (2004) 1.35
Genetic variants of Wnt transcription factor TCF-4 (TCF7L2) putative promoter region are associated with small intestinal Crohn's disease. PLoS One (2009) 1.24
Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology (2010) 1.23
Optimising monitoring in the management of Crohn's disease: a physician's perspective. J Crohns Colitis (2013) 1.20
Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian patients with Crohn's disease: phenotype-genotype correlations. World J Gastroenterol (2005) 1.19
IBD Around the world: comparing the epidemiology, diagnosis, and treatment: proceedings of the World Digestive Health Day 2010--Inflammatory Bowel Disease Task Force meeting. Inflamm Bowel Dis (2011) 1.14
Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology (2013) 1.14
Diagnostic value of CT enteroclysis compared with conventional enteroclysis in patients with Crohn's disease. AJR Am J Roentgenol (2005) 1.11
Interleukin 13 and its role in gut defence and inflammation. Gut (2012) 1.08
Intestinal microbiota: a source of novel biomarkers in inflammatory bowel diseases? Best Pract Res Clin Gastroenterol (2013) 1.06
Specific systemic nonviral gene delivery to human hepatocellular carcinoma xenografts in SCID mice. Hepatology (2002) 1.04
Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology (2013) 1.03
Which patients with IBD need psychological interventions? A controlled study. Inflamm Bowel Dis (2008) 1.03
Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection. J Crohns Colitis (2009) 1.02
A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine. J Hepatol (2005) 1.00
Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARE. Inflamm Bowel Dis (2011) 1.00
Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational study. Inflamm Bowel Dis (2011) 1.00
Infliximab: lack of efficacy on perforating complications in Crohn's disease. Inflamm Bowel Dis (2004) 0.99
A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease. PLoS One (2013) 0.97
Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process. Am J Gastroenterol (2012) 0.97
Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies. Adv Ther (2013) 0.96
6-thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension. Am J Gastroenterol (2007) 0.94
Expression of the high-affinity IgG receptor FcRI (CD64) in patients with inflammatory bowel disease: a new biomarker for gastroenterologic diagnostics. Am J Gastroenterol (2009) 0.93
Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis (2010) 0.92
IBD patients need in health quality of care ECCO consensus. J Crohns Colitis (2008) 0.92
An open-label pilot study of granulocyte colony-stimulating factor for the treatment of severe endoscopic postoperative recurrence in Crohn's disease. Digestion (2003) 0.91
Acupuncture has a placebo effect on rectal perception but not on distensibility and spatial summation: a study in health and IBS. Am J Gastroenterol (2004) 0.91
Endoscopy and MR enteroclysis: equivalent tools in predicting clinical recurrence in patients with Crohn's disease after ileocolic resection. Inflamm Bowel Dis (2010) 0.91
Predictors of indeterminate IFN-γ release assay in screening for latent TB in inflammatory bowel diseases. Eur J Clin Invest (2011) 0.90
Novel variants of the IL-10 receptor 1 affect inhibition of monocyte TNF-alpha production. J Immunol (2003) 0.90
A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease. Scand J Gastroenterol (2015) 0.90
The impact of thiopurines on the risk of surgical recurrence in patients with Crohn's disease after first intestinal surgery. Am J Gastroenterol (2009) 0.90
Extracorporeal photopheresis: past, present, and future. J Am Acad Dermatol (2009) 0.89
Do high serum levels of anti-Saccharomyces cerevisiae antibodies result from a leakiness of the gut barrier in Crohn's disease? Eur J Gastroenterol Hepatol (2003) 0.89
Anastomotic recurrence of Crohn's disease after ileocolic resection: comparison of MR enteroclysis with endoscopy. Eur Radiol (2008) 0.88
Selective Granulocyte and Monocyte Apheresis as a Non-Pharmacological Option for Patients with Inflammatory Bowel Disease. Transfus Med Hemother (2012) 0.88
Association of a functional variant in the Wnt co-receptor LRP6 with early onset ileal Crohn's disease. PLoS Genet (2012) 0.88
Plummer-Vinson syndrome associated with celiac disease and complicated by postcricoid carcinoma and carcinoma of the tongue. Am J Gastroenterol (2003) 0.87
Ecobiotherapy Rich in Firmicutes Decreases Susceptibility to Colitis in a Humanized Gnotobiotic Mouse Model. Inflamm Bowel Dis (2015) 0.86
Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflamm Bowel Dis (2015) 0.86
Results of the 2nd scientific workshop of the ECCO (IV): therapeutic strategies to enhance intestinal healing in inflammatory bowel disease. J Crohns Colitis (2012) 0.86
Factors impacting the results of interferon-γ release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases. Inflamm Bowel Dis (2010) 0.85
Colorectal carcinoma and preceding fistula in Crohn's disease. J Crohns Colitis (2009) 0.85
A systematic survey evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel disease. Wien Klin Wochenschr (2007) 0.85
Tissue factor exposing microparticles in inflammatory bowel disease. J Crohns Colitis (2012) 0.84
Findings at helical CT-enteroclysis in symptomatic patients with crohn disease: correlation with endoscopic and surgical findings. J Comput Assist Tomogr (2002) 0.84
Long-term follow-up of babies exposed to azathioprine in utero and via breastfeeding. J Crohns Colitis (2010) 0.84
Austrian infliximab experience in Crohn's disease: a nationwide cooperative study with long-term follow-up. Eur J Gastroenterol Hepatol (2004) 0.83
Thioguanin-induced nodular regenerative hyperplasia of the liver-ROC analysis of different MR techniques. Eur Radiol (2007) 0.83
Three novel thiopurine S-methyltransferase allelic variants (TPMT*20, *21, *22) - association with decreased enzyme function. Hum Mutat (2006) 0.83
Portal vein thrombosis in ulcerative colitis complicated by bleeding from gastric varices. Inflamm Bowel Dis (2007) 0.82
Drug monitoring of biologics in inflammatory bowel disease. Curr Opin Gastroenterol (2013) 0.82
Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease. Gastroenterology (2012) 0.82
Alterations in intestinal permeability following the intensified polydrug-chemotherapy IFADIC (ifosfamide, Adriamycin, dacarbazine). Cancer Chemother Pharmacol (2002) 0.82
Change in erythrocyte mean corpuscular volume during combination therapy with azathioprine and infliximab is associated with mucosal healing: a post hoc analysis from SONIC. Inflamm Bowel Dis (2015) 0.82
Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: results from the CARE trial. J Crohns Colitis (2012) 0.81
Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study. Inflamm Bowel Dis (2015) 0.81